These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32878882)

  • 1. Alpha-synuclein aggresomes inhibit ciliogenesis and multiple functions of the centrosome.
    Iqbal A; Baldrighi M; Murdoch JN; Fleming A; Wilkinson CJ
    Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.
    Tanaka M; Kim YM; Lee G; Junn E; Iwatsubo T; Mouradian MM
    J Biol Chem; 2004 Feb; 279(6):4625-31. PubMed ID: 14627698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly.
    Oikawa T; Nonaka T; Terada M; Tamaoka A; Hisanaga S; Hasegawa M
    J Biol Chem; 2016 Jul; 291(29):15046-56. PubMed ID: 27226637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggresome-related biogenesis of Lewy bodies.
    McNaught KS; Shashidharan P; Perl DP; Jenner P; Olanow CW
    Eur J Neurosci; 2002 Dec; 16(11):2136-48. PubMed ID: 12473081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synphilin isoforms and the search for a cellular model of lewy body formation in Parkinson's disease.
    Eyal A; Engelender S
    Cell Cycle; 2006 Sep; 5(18):2082-6. PubMed ID: 16969096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
    Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
    Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson's Disease and Dementia with Lewy Bodies.
    Power JH; Barnes OL; Chegini F
    Brain Pathol; 2017 Jan; 27(1):3-12. PubMed ID: 26667592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
    O'Hara DM; Kalia SK; Kalia LV
    Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
    Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
    Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
    Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
    J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
    Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
    Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graphene quantum dots prevent α-synucleinopathy in Parkinson's disease.
    Kim D; Yoo JM; Hwang H; Lee J; Lee SH; Yun SP; Park MJ; Lee M; Choi S; Kwon SH; Lee S; Kwon SH; Kim S; Park YJ; Kinoshita M; Lee YH; Shin S; Paik SR; Lee SJ; Lee S; Hong BH; Ko HS
    Nat Nanotechnol; 2018 Sep; 13(9):812-818. PubMed ID: 29988049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
    Wang R; Sun H; Ren H; Wang G
    Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions.
    Gadhavi J; Patel M; Bhatia D; Gupta S
    Biochimie; 2022 Jan; 192():38-50. PubMed ID: 34582997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.